Roth Capital Upgrades Medivation (MDVN) to Buy
More News related to MDVN
- Medivation (MDVN) March call volume and volatility elevated into data
- Medivation to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
- Roth Capital Upgrades Medivation (MDVN) to Buy
- Medivation (MDVN) Reports Q3 Loss of $0.42, Misses by 3c
- Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
Roth Capital upgrades Medivation (Nasdaq: MDVN) from Hold to Buy. Price target increased from $21 to $34.
To see more analyst ratings on MDVN Click Here.
Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer.
Related Categories
UpgradesStocks Mentioned
-0.51Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
